- To provide an update on the role of angiogenesis and the importance of its targeting in the management of patients with ovarian cancer
- To provide an update on anti-angiogenic targets and compounds, currently approved for treatment of ovarian cancer or under development
- To provide an update from clinical studies with anti-angiogenic therapies in first-line setting, platinum-sensitive and platinum-resistant recurrent ovarian cancer
After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module.
|Title||Duration||Content||CME Points||CME Test|
|Targeting Angiogenesis in Ovarian Cancer||31 min.||53 slides||-||-|
Therapeutic targeting of angiogenesis is one of the most intensive areas in drug research today. Bevacizumab was the first targeted agent and currently remains the only anti-angiogenic drug approved for use in patients with ovarian cancer. Despite this drug’s approval, there is a general impression that it is still underused in the oncology practice.
Therefore, this module on targeting the angiogenesis, with a comprehensive overview of different targets, targeting strategies and anti-angiogenic compounds, is timely released. It provides an excellent review of drugs activity and clinical outcomes in different settings of ovarian cancer.
In the first-line setting bevacizumab prolongs progression-free survival (PFS). Clinical trials with tyrosine kinase inhibitors showed prolonged PFS when they are given concurrently with chemotherapy in case of nindetanib or as maintenance in case of pazopanib. Other drugs are under investigation.
In terms of platinum-sensitive recurrent ovarian cancer, when given with chemotherapy, bevacizumab prolongs PFS. Prematurely closed study with cediranib’s combination with chemotherapy showed prolonged PFS and overall survival. There is no data in patients pretreated with bevacizumab. Treatment with bevacizumab beyond progression is currently under evaluation.
In terms of platinum-resistant recurrent ovarian cancer, bevacizumab and trebanabib, both in combination with chemotherapy, prolong PFS. A combination of anti-angiogenic drug with weekly paclitaxel seems to be the most effective. Multiple agents are under investigation and as in the platinum-sensitive disease there is no data in patients pretreated with bevacizumab.
The authors conclude that anti-angiogenic drugs are active in first-line and maintenance setting, resistant and sensitive disease, with no doubt that targeting the angiogenesis is crucial in ovarian cancer. However, no predictive biomarker has been identified. They predict that 3-4 different anti-angiogenic agents might be approved in the future. Currently, there is no available data on sequences, treatment beyond progression or cross resistance. These areas remain to be addressed by ongoing and future research.
This E-Learning module is an excellent CME opportunity for all oncologists with interest in gynaecologic malignancies and those keen to learn essential updates from the latest data in this area of clinical cancer research.
This E-Learning module was published in 2014 and expired in 2017.
The authors have reported no conflict of interest